Semaglutide is a part of a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists, and theyre used to treat diabetes and weight loss by interacting with the hunger part of the brain to suppress the appetite, and lowering blood sugar and A1C
For Zepbound, singleuse vials pose safety risks if reused
BCN Pre & Post and BCN Prebiotics: Round out the portfolio with topical professional skincare designed for patient maintenance between in-clinic sessions
FDAs concerns with unapproved GLP-1 drugs used for weight loss, United States Food and Drug Administration (2024) FDA approves first oral GLP-1 treatment for Type 2 diabetes, United States Food and Drug Administration (2019) Semaglutide for Type 2 diabetes, CADTH Health Technology Review (2023) Anti-inflammatory benefits of semaglutide: State of the art, Journal of Clinical & Translational Endocrinology (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Marc Jean-Gilles, DO, FACOG , offers personalized advice, ensuring each patient receives the most appropriate treatment tailored to their needs